紫杉醇脂质体联合顺铂用于转移性或晚期宫颈癌患者一线治疗的近期临床疗效观察及安全性分析

Evaluation Clinical Efficacy and Safety of Paclitaxel Liposome Combined with Cisplatin as First-Line Chemotherapy in the Metastatic or Advanced Cervical Cancer Patients

摘要: 目的：紫杉醇脂质体联合顺铂用于转移性或晚期宫颈癌患者一线治疗的近期疗效观察和安全性分析。方法：选取2015年1月至2016年12月在西京医院肿瘤科住院的转移性或晚期宫颈鳞癌患者，共24例患者。接受不少于2周期的治疗。每2周期进行疗效及安全性评估，主要观察指标包括客观缓解率(Objective Response Rate, ORR)、疾病控制率(Disease Control Rate, DCR)、无进展生存期(Progression-Free Survival PFS)和不良反应。结果：完全缓解(Cmplete remission represents, CR) 3例(12.5%)，部分缓解(Partial Remission, PR) 7例(29.2%)，稳定(Stable Disease, SD) 10例(41.7%)，病情进展(Progressive Disease, PD) 4例(16.6%)。ORR为41.7% (10例)，DCR为83.4% (20例)，中位PFS 8.7月(2.3~16.6月)。安全性评估：3级及以上不良反应包括中性粒细胞减少(6例，25%)、血小板减少(4例，16.6%)、总胆红素升高(3例，12.5%)、神经毒性(2例，8.4%)。结论：紫杉醇脂质体联合顺铂用于宫颈癌一线化疗具有良好的疗效和安全性。

Abstract: Objective: The objective of the study was to evaluate clinical efficacy and safety of paclitaxel lipo-some combined with cisplatin as first-line chemotherapy in the metastatic or advanced cervical cancer patients. Methods: The clinical data of 24 patients with the metastatic or advanced cervical cancer in department of oncology in xijing hospital from Jan. 2015 to Dec. 2016 were retrospectively analyzed. The efficacy and safety of each patient were evaluated after 2 cycles of treatment, and the main observation indexes included ORR, DCR, PFS and adverse reactions. Results: Three patients (12.5%) had CR, seven patients (29.2%) had PR, ten patients (41.7%) had SD and four patients (16.6%) had PD. ORR was 41.7%. DCR was 83.4%. Median PFS was 8.7 months (2.3 - 16.6 months). Level 3 and above grade toxic effects: Neutropenia (6, 25%), Thrombopenia (4, 16.6%), Elevated TBIL (3, 12.5%) and Neurotoxicity (2, 8.4%). Conclusion: Paclitaxel liposome combined with cisplatin as first-line chemotherapy of the metastatic or advanced cervical cancer has good efficacy and reliable safety.